ABL001 is effective for the treatment of CML patients with BCR::ABL1 single mutations but has a limited effect on those with BCR::ABL1 compound mutations (Eide et al., 2019), which has been further verified at the cellular level in this study. Here, BCR is linked to chronic myelogenous leukemia, BCR-ABL1 positive.